Futura's innovation strategy applies advanced science to develop products with compelling commercial potential using our advanced proprietary transdermal technology.

Our research and development strategy

We focus exclusively on topically applied pharmaceutical drugs, ancillary medicinal substances and functional excipients for the over the counter and prescription markets. We only incorporate existing well-characterised chemical entities into our products. This strategy gives us a lower development risk profile compared with developing new chemical entities. As a result, the overall risk of the investment is reduced as our strategy increases the likelihood of regulatory approval and lowers the cost of development.

A product pipeline entering its commercialisation phase

We specialise in sexual health and pain relief and have five core products in our development pipeline:

Sexual Heath


CSD500

MED2002

Pain relief


TPR100

TIB200

SPR300